Sandoz' Gene Therapy In Brain Cancer

6 October 1996

- An efficacy trial of gene therapy in brain cancer patients has been initiated by Sandoz Pharmaceuticals. The therapy, GLI-328, is to be administered post-surgically in about 250 patients in 40 centers worldwide. A gene derived from a Herpes simplex virus will be transferred and incorporated into the DNA of the glioblastoma tumor cells. The enzyme produced, thymidine kinase, renders cells susceptible to Roche's ganciclovir which is subsequently administered, causing the destruction of cancer cells.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight